| |||||||
iCell Cardiomyocytes — highly purified in the quantities you need.
Applications include targeted drug discovery, toxicity testing, and other life science research…
Learn more about iPS 2.0™: CDI's induced, pluripotent stem (iPS) stem cell technology that coaxes the full potential from adult tissue or blood cells to generate a range of unique, terminally differentiated cells lines for in vitro research and drug discovery applications.
January 22, 2010
MIT Technology Review: Made-to-Order Heart Cells
January 2010
Nature Methods:
IPSCs: One Cell to Rule Them All?
December 16, 2009
Cellular Dynamics Announces Commercial Launch of iCell™ Cardiomyocytes for Drug Candidate Toxicity Screening
September 20, 2009
Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing
November 3, 2009
Large-Scale Production of Human iPS Cell-Derived Cardiomyocytes
– Workshop at the American College of Toxicology (ACT) Annual Meeting,
Cellular Dynamics is the world’s largest producer of fully functional human cells derived from induced pluripotent stem (iPS) cells. Our iCell™ products provide industrialized quantities of genetically diverse, terminally differentiated human cells enabling basic research, efficient drug discovery programs, and reliably predictive toxicity and efficacy screening through in vitro clinical trials.
